BioSpace News Archive

Nicoya, a leading provider of advanced analytical instruments for the biotechnology and pharmaceutical industries, will receive advisory services and up to $299,190 in research and development funding from the National Research Council of Canada Industrial Research Assistance Program (NRC IRA

Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side effects, announced today that it has appointed Dr. Erez Scapa to its Scientific Board of Advisors.

Inovalon, a leading provider of cloud-based platforms empowering data-driven healthcare, announced a five-year engagement with Cardinal Health, Inc., a global integrated healthcare services and products company, to provide a configuration of Inovalon’s ScriptMed® Cloud.

Investigators at Nagourney Cancer Institute will report at the AACR Virtual Annual Meeting, June 22-24, that Alpelisib (BYL 719), an inhibitor of PI3Kα, that was recently approved for ER-Positive breast cancer in combination with Fulvestrant

Phanes Therapeutics, Inc. (Phanes), an emerging leader in innovative discovery research in immuno-oncology announced today that it has developed a proprietary bispecific antibody technology platform, PACbodyTM

International, multi-center, randomized, double-blind, placebo-controlled clinical study targeting the prevention of Acute Respiratory Distress Syndrome (ARDS) and Acute Kidney Injury (AKI) in patients infected with COVID-19 Novel Mechanism of Action - a selective dipeptidase-1 antagonist that prevents leukocyte adhesion to endothelial cells reducing inflammation and subsequent organ damage Study also recently approved by Health Canada TORONTO, June 16, 2020 (GLOBE NEWSWIRE) --

Long-term follow-up of more than 2,000 people enrolled in the Diabetes Prevention Program Outcomes Study (DPPOS) indicates a continued significant reduction in the participants’ risk of developing type 2 diabetes (T2D).

An important webinar addressing the prevention, detection and treatment of Lyme disease—an affliction that impacts as many as 400,000 Americans each year—will be held on June 25, coinciding with the annual early stages of “Lyme season” in the United States.

Mesa Laboratories, Inc. (NASDAQ: MLAB) (“Mesa Labs”) today announced that the underwriters for its previously announced public offering of common stock have fully exercised their option to purchase 90,000 additional shares of Mesa Labs common stock.

Avanir Pharmaceuticals, Inc. and The UCI Paul Merage School of Business are pleased to announce the appointment of two new executives to the School’s Center for Health Care Management and Policy advisory board. Wa’el Hashad, president and CEO of Avanir Pharmaceuticals,